Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Evidence-Based Practice in Social Work Education

NCT07856966 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-01-01
Last updated
2026-10-05

Condition(s) studied

Evidence-Based Practice

Investigational drug(s) / intervention(s)

Evidence-Based Practice Education

Evidence-Based Practice Education: Participants will receive a one-semester evidence-based practice education program integrated into a social work course. The program will include instruction and practical activities related to formulating practice questions, searching for and appraising research evidence, integrating evidence with professional judgment and client circumstances, applying evidence to social work practice, and evaluating practice decisions. All participants will receive the same educational intervention.

Study summary

This educational intervention study evaluates evidence-based practice (EBP) education among social work students. The study will assess changes in students' engagement with the EBP process, attitudes toward evidence-based interventions, information literacy, and perceived social work competence following the educational intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Aged 18 years or older; 2. Currently enrolled as a social work master's student in the participating one-semester course; 3. Able to understand and complete the study questionnaires in Chinese; 4. Willing to participate and provide informed consent. Exclusion Criteria: 1. Not enrolled in the participating course during the study period; 2. Declines to provide informed consent;

Primary outcome measure(s)

  • Change in Evidence-Based Practice Process Assessment Scale (EBPPAS) score — Baseline, 3 months (mid-intervention), and 6 months (immediately after completion of the course)
    The primary outcome is the change in participants' EBPPAS score from baseline to post-intervention. The EBPPAS assesses participants' evidence-based practice process outcomes. Items are rated on a 5-point response scale, with higher scores indicating more favorable evidence-based practice process outcomes.

Trial sites (1)

FacilityCityRegionStatus
Beijing Normal University Zhuhai Guangdong
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07856966 on ClinicalTrials.gov ↗ ← All trials in China